Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece

Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece

ObjectiveHigher valency pneumococcal conjugate vaccines (PCVs) are expected to improve protection against pneumococcal disease through coverage of additional serotypes. The aim of the present study was to evaluate the cost-effectiveness of 20-valent pneumococcal conjugate vaccine (PCV20) compared to...

Full description

Bibliographic Details
Main Authors: George Gourzoulidis, Myrto Barmpouni, Vasiliki Kossyvaki, Jeffrey Vietri, Charalampos Tzanetakos
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-09-01
Series:Frontiers in Public Health
Subjects:
PCV20
PCV15
pneumococcal disease
Greece
pneumococcal conjugate vaccines
Online Access:https://www.frontiersin.org/articles/10.3389/fpubh.2023.1229524/full

Internet

https://www.frontiersin.org/articles/10.3389/fpubh.2023.1229524/full

Similar Items